COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Anticardiolipin antibody syndrome and Drug allergy (Sulfa). Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN 81) for an unknown indication.   On 06-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 09-May-2022 to 14-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   On 15-MAY-2022: Patient had Rebound covid.  Company comment: This spontaneous case concerns an adult female patient of unknown age, with relevant medical history of Anticardiolipin antibody syndrome, who experienced the unexpected non serious AESI of COVID-19, about 5 months and 5 days after receiving the third dose with mRNA-1273 vaccine in the COVID-19 vaccination series. The patient received the previous two doses with mRNA-1273 vaccine, the last dose being given about 8 months and 4 days prior to the third dose, with no reported adverse events. The interval between the first and second doses was not disclosed in the report. It was noted that the patient took Paxlovid for COVID-19 for 5 days and had a COVID-19 rebound on the sixth day. No further information on COVID-19 tests was available in the report. The event was not resolved. The ongoing COVID-19 pandemic and medical history of Anticardiolipin antibody syndrome could be risk factors for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns an adult female patient of unknown age, with relevant medical history of Anticardiolipin antibody syndrome, who experienced the unexpected non serious AESI of COVID-19, about 5 months and 5 days after receiving the third dose with mRNA-1273 vaccine in the COVID-19 vaccination series. The patient received the previous two doses with mRNA-1273 vaccine, the last dose being given about 8 months and 4 days prior to the third dose, with no reported adverse events. The interval between the first and second doses was not disclosed in the report. It was noted that the patient took Paxlovid for COVID-19 for 5 days and had a COVID-19 rebound on the sixth day. No further information on COVID-19 tests was available in the report. The event was not resolved. The ongoing COVID-19 pandemic and medical history of Anticardiolipin antibody syndrome could be risk factors for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.